1. Introduction {#sec1}
===============

Peroxisome proliferator-activated receptor *γ* (PPAR*γ*) coactivator 1*α* (PGC-1*α*) is an important coactivator of several nuclear receptors regulating mitochondrial function in various tissues including brain, heart, skeletal muscle, and liver[@bib1]. PGC-1*α* was initially discovered as one of the PPAR*γ*-binding proteins present in brown adipose tissue as a response to cold treatment. PGC-1 coactivators were reported to possess a vast range of biological effects in different tissues. Indeed, PGC-1 transcriptional coactivators were revealed to have an essential role in physiological adaptation *via* many signaling cascades[@bib2]. PGC-1*α* regulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-*κ*B) pathway by modulating inflammatory processes in muscle cells, and the targeting of PGC-1*α* in chronic diseases may thus reduce inflammation[@bib3]. PGC-1*α* has been found to act as a reactive oxygen species (ROS) scavenging enzyme regulator that contributes to the survival of neurons[@bib4]. More to the point, in earlier reports, PGC-1 coactivators were found to possess an important role in skeletal muscle biology by inducing mitochondrial biogenesis, muscle fiber-type switching[@bib4]^,^[@bib5], and functional angiogenesis in skeletal muscle[@bib6] ([Fig. 1](#fig1){ref-type="fig"}). Indeed, PGC-1 was reported to enhance GA-binding protein (GABP) which is an important transcription factor controlling the genes involved in forming neuromuscular junctions (NMJ)[@bib7]. Furthermore, GABP activation has been shown to induce utrophin promoter activity in muscle cells and in muscle tissues[@bib8].Figure 1Speculative model of the role of PGC-1*α* in the regulation of angiogenesis during exercise and in response to ischemia.Figure 1

A variety of studies have looked into the PPAR*γ*-activating effects of natural products derived from medicinal plants. Resveratrol, honokiol, biochanin A, genistein, sargahydroquinoic acid, amorphastilbol, sargaquinoic acid, magnolol, amorfrutin 1, and amorfrutin B were demonstrated to display modulatory effects on PPAR*γ* activation with fewer side-effects compared to synthetic drugs[@bib9]. Therefore, in this review, we aimed to summarize the current knowledge on muscular dystrophy (MD), focusing on the potential effects of natural compounds which act as regulatory agents on PGC-1*α*.

2. Duchene muscular dystrophy (DMD) {#sec2}
===================================

Degenerative disorders targeting muscles, which arise from genetic anomalies in the expression of genes in muscle tissues, are known as MDs[@bib10]. MDs are a set of diseases indicated by the extensive wasting of skeletal muscles due to mutations in genes responsible for linkage formation between the cytoskeleton and the basal lamina[@bib11]^,^[@bib12]. Dystrophin protein (427 kDa) is a cytoplasmic protein which links with numerous other proteins in the formation of the dystrophin-associated glycoprotein complex (DAGC) responsible for hooking up the cytoskeleton of muscle fibers with the surrounding extracellular matrix (ECM) by means of the cell membrane[@bib11]. DAGC connects muscle fiber cytoskeletal structures with the extracellular matrix and thus ensures the structural integrity of muscle fibers[@bib13]^,^[@bib14]. MDs are considered to be a group of heterogeneous disorders, of which the most severe and common form is DMD[@bib15], named in 1868 after Guillame Duchenne, a renowned neurologist who described 13 boys affected by this disorder[@bib16]. Despite the passing of two centuries from its first description, no cure has been found for DMD to date and it remains a fatal condition. DMD is accepted as an X-linked recessive disorder caused by a dystrophin gene mutation which leads to a loss in expression of functional dystrophin, a cytoskeletal protein responsible for facilitating the functionality, stability, and strength of myofibres[@bib18]. The key characteristic of DMD is irreversible and extreme skeletal muscle degeneration associated with physical incapacitation. Moreover, several patients also suffer from weakness of the intercostal muscles and diaphragm which leads to terminal respiratory failure before 25 years of age[@bib10]. The consequences of dystrophin inexpression in cardiac purkinje fibers and cardiomyocytes give rise to progressive cardiomyopathy and arrhythmia, leading to heart failure in approximately 10% DMD patients[@bib10]^,^[@bib19]. DMD affects approximately 1:5000 newborn males and occurs in one in every 3500--5000 males born across the world[@bib20]^,^[@bib21].

DMD\'s prevalence has been reported as 19.5 cases in 100,000 live male births in the UK. The incidence in the USA is 15.9 cases per 100,000[@bib22], [@bib23], [@bib24]. A recent study reported that the methods for diagnosing DMD have remained the same since around 2010[@bib18]. DMD is sometimes considered to be an X-linked myopathy, leading to progressive wasting of respiratory and locomotor muscles. The resultant chronic ventilatory failure has been identified as a major cause of death[@bib25]. Absence or deficiency of dystrophin may lead to progressive wasting of skeletal muscle and lethal heart failure.

Effective treatment and overall care for DMD is required to prevent the death of children during adolescence or early adulthood. Despite the exploration of several therapies, only corticosteroids showed effective benefits[@bib17]. Novel therapeutic approaches based on prior studies in animal models are currently undergoing clinical experimentation with encouraging results. These include therapies aiming at restoring dystrophin expression and others aiming at compensating for the deleterious consequences of its absence in skeletal muscle. Description of novel therapeutic approaches is far beyond the scope of this review[@bib26].

Read-through, exon skipping, and vector-mediated genetic and cell therapies have been used to restore the expression of dystrophin, whereas pharmacological treatments include anti-inflammatory, anti-fibrotic, antioxidant agents, myostatin pathway inhibition, neuronal nitric oxide synthase pathway enhancement, and utrophin upregulation therapies. Read-through therapy applies to 10% of patients with nonsense mutations, resulting in a premature stop codon in dystrophin mRNA[@bib27].

Of the compounds that can read through premature nonsense codons, ataluren (PTC124) is currently available online in Europe[@bib28].

In patients with DMD, exon-skipping, applicable to 80% of mutations, can correct the altered reading frame by targeting the exon to be skipped with antisense oligonucleotides (ASOs). Skipping a gene would hypothetically be of therapeutic relevance for various mutation series[@bib29] as DMD is one of the largest genes known with 79 exons[@bib30]^,^[@bib31]. A functional, shorter, dystrophin is produced by this process, effectively converting a severe DMD phenotype to a milder Becker muscular dystrophy (BMD) phenotype. The major ASO developed to skip exon 51 was eteplirsen[@bib32].

Conditional approval was granted to eteplirsen by the U.S. Food and Drug Administration (FDA) in 2016. Exon skipping therapies have grown to target other exons with time. Dystrophin protein production is restored in DMD by means of vector-mediated gene therapy, delivering micro/mini domains of dystrophin through either viral or non-viral vectors[@bib21]^,^[@bib33], [@bib34]^--^[@bib35]. Clinical trials are currently underway for adeno-associated virus (AAV) vectors, finalized for micro-dystrophin gene transfer[@bib36].

Cell therapy involves the transplanting of either cells provided by healthy donors or genetically corrected autologous cells, both capable of producing functional dystrophin[@bib37]. Myoblasts[@bib38], CD133^+^ stem cells[@bib39], and mesoangioblasts[@bib40] are undergoing clinical trials as potential therapeutic candidates, which are chosen from a wider range of viable cell types. Of the cell therapy options, investigations are currently ongoing on induced pluripotent stem cells (iPSCs) taken from DMD, umbilical cord mesenchymal stem cells, and bone marrow-derived autologous stem cells. Human iPS-derived myogenic cells have been transplanted into *mdx* mice (the most popular animal model for DMD carrying a point mutation in DMD gene), resulting in human-derived dystrophin-positive muscle fibers and an improvement in muscle strength[@bib41].

CRISPR/Cas9 technology has been used to induce frame shifting, exon knock-in, and exon skipping in patient-derived human iPS cells, raising the possibility of *ex-vivo* gene correction followed by autologous cell transplantation for DMD patients[@bib42], [@bib43], [@bib44]. However, there are serious limitations on treating DMD patients with current cell therapy technology, including limits on cell availability, low survival, and migration rates for injected cells, the risk of tumor formation, and the immune response to donated cells, with no effective treatment available at present for the prevention of the progression and occurrence of this lethal disease condition[@bib13]^,^[@bib22]^,^[@bib45]^,^[@bib46].

Pharmacological therapy represents an additional fundamental approach mainly utilized to limit complications, *i*.*e*., inflammation, atrophy, and fibrosis, generally associated with the dystrophic process, which can worsen the evolution of the disease and severely limit the effectiveness of other therapies such as gene or cell therapy. In particular, it has been shown that the evolution to fibrosis in DMD is mainly promoted by an excessive inflammatory response[@bib47]. Several therapeutic strategies, including prednisone, deflazacort, and NF-*κ*B inhibitors, have been used to address inflammation in combination with cell therapy and exon skipping, with promising results[@bib48]^,^[@bib49].

A novel steroid analog, vamorolone, which lacks hormonal or immunosuppressive effects, is also under recent investigation for its safety and efficacy[@bib50].

Relevant results have been also obtained with nitric oxide (NO) donors and deacetylase inhibitors targeting events downstream of the genetic defect in both a mouse model of limb girdle muscular dystrophy and in adult dystrophic patients. In particular, the use of nonsteroidal drugs (hydrochlorothiazide, HCT) which act as NO donors has been shown to counteract the progression of the dystrophic process in a mouse model of limb girdle MD and in humans[@bib51]^,^[@bib52].

Studies in animal models have also reported that insufficient dystrophin deregulates histone deacetylase (HDAC) activity, and this is followed by progression of the disease through activation of compensatory regeneration and/or fibroadipogenic degeneration, thus supporting histone deacetylase inhibitors as potentially effective pharmacological interventions to counteract disease progression in dystrophic patients. The beneficial effects of long lasting HDAC inhibitor exposure have been found in *mdx* mice *α*-sarcoglycan null mice in a model of limb girdle muscular dystrophy[@bib53].

The effects of HDAC inhibitor givinostat have recently been investigated in DMD patients and a phase 3, randomized, double-blind, placebo-controlled study is currently ongoing[@bib54].

Important emerging research highlights that deregulation of NO signaling to HDAC contributes to the pathogenesis of the disease. It has been found that the absence of dystrophin at the sarcolemma in *mdx* mice downregulates NO synthase (NOS), leading to the deficient *S*-nitrosylation of HDAC2, which controls the follistatin gene, and this event may ultimately promote muscle degeneration.

Direct inhibition of HDAC2 by HDAC inhibitors, or inactivation by either NO donors, may lead to the derepression of follistatin, thus promoting myogenesis and disease amelioration[@bib55].

These results indicate that HDAC, with HDAC2 in particular, is an important common pharmacological target for distinct pharmacological interventions (for histone deacetylase inhibitors, see the other review[@bib56]).

3. The PGC-1 coactivators {#sec3}
=========================

Coactivators can regulate target gene expression by specifically affecting protein--protein interactions through known transcription factors possessing DNA-binding activity. Therefore, they act as transcriptional regulators which do not directly bind to target gene promoters. For example, myogenic differentiation (MyoD) or PPAR*γ* can induce the differentiation of muscle or adipose cells[@bib57].

Transcription may be enhanced by association with RNA polymerase machinery, or by altering the chromatin structure in target gene promoters[@bib57].

A coactivator may sometimes interact with several transcription factors and *vice versa*[@bib57]. Although these interactions are versatile, they depend on certain protein interacting interfaces and signaling cues that promote the activation of transcription factors[@bib58].

The expression of PGC-1 coactivators was first implicated in thermogenesis and regulation of energy metabolism[@bib49]. However, studies have concluded that it acts in a broader context, and the overexpression of PGC-1 promotes mitochondrial biogenesis as well as key mitochondrial functions[@bib57]^,^[@bib59]. In fact, these coactivators are important in maintaining the homeostasis between glucose, lipids, and energy[@bib60]. PGC-1 is also involved in other pathological conditions, such as obesity, cardiomyopathy, and neurodegeneration[@bib58].

PGC-1*α* was the first member of the PGC-1 family identified. It was found as a PPAR*γ*-interacting protein in brown adipose tissue. PGC-1*β* is another member of this family and the closest homolog of PGC-1*α*. Other members have limited homology[@bib58].

Overall, studies on *Pgc-1α* transgenic mice have showed remarkable tissue effects due to its overexpression, thus stimulating subsequent analysis of the role of its physiological expression in fundamental mechanisms in skeletal muscle and fat[@bib61].

In particular, PGC-1*α* has been found to exert a role in brown adipose tissue, unlike transdifferentiation. Moreover, PGC-1 coactivators were found to be important in differentiation-induced mitochondrial biogenesis[@bib59].

PGC-1*α* has interactions with a wide range of transcription factors, including nuclear respiratory factors, nuclear hormone receptors, and muscle-specific transcription factors, reacting to environmental stimuli[@bib60].

Summermatter et al.[@bib62] reported that PGC-1*α* is responsible for the estrogen-related-*α*-dependent expression of lactate dehydrogenase B (LDH B) in skeletal muscle, and for the repression of lactate dehydrogenase A (LDH A). Therefore, PGC-1*α* coordinates lactate homeostasis, alters the composition of the LDH complex, and prevents the increase of lactase in blood during exercise.

ROS, such as superoxides, can damage DNA, lipids, and proteins, and are the originators of ischemia--reperfusion injury, aging, and neurodegenerative diseases, such as Alzheimer\'s disease, Parkinson\'s disease, and Huntington\'s disease. St-Pierre et al.[@bib63] reported that PGC-1*α*, which has the ability to increase the activity of mitochondrial electrons, is a regulator of ROS metabolism. Therefore, new therapies should be investigated for controlling these pathophysiological conditions and thus inducing PGC-1*α* in the brain. While this is not an easy task, PGC-1*α* is inducible in many tissues and responds to important metabolic pathways of calcium and cyclic adenosine monophosphate (AMP) signaling[@bib63]. In fact, Zheng et al.[@bib64] identified PGC-1*α* as a promising factor in the early treatment of Parkinson\'s disease, as PGC-1*α* are underexpressed in these patients. The capacity of PGC-1*α* to control energy homeostasis indicates its possible suitability as a target for antidiabetic or antiobesity drugs[@bib60]^,^[@bib65].

The involvement of PGC-1 in controlling mitochondrial biogenesis and energy metabolism was hotly pursued after its discovery in the 1990s^66^. The three PGC-1 coactivators were reported to control the mitochondrial metabolism in different ways despite their structural similarities, and thus different modes of action. PGC-1*α* is induced by various stimuli; whereas PGC-1*β* is stimuli-unresponsive and maintains basal mitochondrial function; the action of the third PGC-1 member, PGC-1-related coactivator, is apparently limited to regulating gene expression and mitochondrial metabolism in highly proliferating cells. PGC-1 coactivators bind to various transcription factors or nuclear receptors which orchestrate target genes expression[@bib67].

The role of the transcriptional coactivator PGC-1 in oxidative stress, inflammation, and angiogenesis is discussed in the following sub-sections, along with its mechanisms of action.

3.1. The role PGC-1α in oxidative stress {#sec3.1}
----------------------------------------

PGC-1*α* and PGC-1*β* have emerged as major players that integrate signaling pathways and exert protective actions against oxidative stress. They are also recognized as key factors in many oxidative stress response programs.

In particular, PGC-1*α* can serve as a master regulator of the oxidative metabolism and mitochondrial biogenesis, thus acting as a key regulator of ROS primarily generated by mitochondria. It is widely reported that PGC-1*α* modulates ROS scavenging enzymes, including the mitochondrial proteins manganese superoxide dismutase 1 and 2 (SOD1 and SOD2) and the uncoupling proteins 1 and 2 (UCP1 and UCP2)[@bib66]^,^[@bib68]. Indeed, overexpression of PGC-1*α* results in an increased expression of SOD2 in SH-SY5Y neuroblastoma cells[@bib69], and depletion of PGC-1*α* by siRNAs prevents the upregulation of SOD1 and SOD2, as well as glutathione peroxidase 1 (GPX1), another ROS scavenging enzyme, together with UCP1 and UCP2, indicating that PGC-1*α* controls cytoprotective responses[@bib63]^,^[@bib70].

Furthermore, PGC-1 (both *α* and *β*) gene expression increases alongside antioxidant defences, under induction of oxidative stress by H~2~O~2~ treatment of mouse embryonic fibroblasts; conversely, PGC-1 depletion prevents the increased expression of genes responsible for ROS detoxification in response to H~2~O~2~^63^, suggesting a protective role of PGC-1 under effects of oxidative stress.

In many diseases, overproduction of ROS by dysfunctional mitochondria has been associated with decreased PGC-1*α* expression. For example, PGC-1*α* levels were found to be lower in the kidneys of diabetic rats; while by inducing PGC-1*α* overexpression, ROS generation was inhibited *via* the modulation of dynamin-related protein 1 (DRP1)-mediated mitochondrial dynamics, with a consequent improvement in glomerular mesangial cell function[@bib71].

Interestingly, in Down syndrome (DS), a neurodevelopmental disease associated with mitochondrial dysfunction and oxidative stress[@bib72], down-regulation of PGC-1*α* protein levels and activity has been found in fibroblasts as well as in neural cells taken from the hippocampus of DS mouse[@bib73]^,^[@bib74]. DS is a genetic disease characterized by cognitive impairment associated with early neurodegeneration and aging as well as muscular weakness[@bib75].

PGC-1*α* activation is regulated by three systems: PPARs, 5′ adenosine monophosphate-activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (SIRT1)[@bib76]. AMPK phosphorylation promotes expression and activation of PGC-1*α*[@bib77]; similarly, SIRT1 deacetylates and activates PGC-1*α*, thereby regulating mitochondrial biogenesis[@bib78].

NO has been found to activate PGC-1*α* through AMPK or in a P53-dependent manner, with the possible involvement of multiple pathways simultaneously[@bib79]. NO has also been found to prompt the expression of SIRT1 deacetylase inducer, acting *via* cyclic guanosine monophosphate (cGMP)[@bib80]^,^[@bib81]. Thus, the alteration of AMPK/SIRT1 pathways, proven to occur in DS[@bib74]^,^[@bib82], has been suggested to account for a decrease in PGC-1*α* activity, and therefore for mitochondrial dysfunction and ROS, which play central roles in the pathogenesis of DS[@bib72] and in that of neurodegenerative diseases, including Alzheimer\'s, Huntington\'s, and Parkinson\'s diseases[@bib75]^,^[@bib83]. Activation of PGC-1*α* by pharmacological agents has been proven to improve oxidative stress and clinical phenotype in oxidative stress-related diseases. For instance, nutraceuticals including resveratrol, administered *via* SIRT1 induction, and thiazolidinediones, which induce PPAR*γ* activation, have been reported to counteract oxidative stress and resultant mitochondrial dysfunction in mouse models of neurodegenerative disease[@bib84]^,^[@bib85]. In addition, polyphenols, resveratrol, and epigallocatechin-3-gallate (EGCG), have been demonstrated to reverse mitochondrial dysfunction and reduce oxidative stress in DS cells by acting through the PGC-1*α*/SIRT1/AMPK axis[@bib74]^,^[@bib86]. Metformin, which activates PGC-1*α via* AMPK induction, has recently been shown to restore the mitochondrial network and to counteract mitochondrial dysfunction and ROS generation in heart fibroblasts with chromosome 21 trisomy[@bib87].

Notably, several signaling pathways related to PGC-1*α* activation/function are deregulated in MD, which in turn results in a reduced capacity for mitochondrial oxidative phosphorylation[@bib88] and the detoxification of ROS[@bib89]. In the light of these results, an early pharmacological intervention aimed at activating PGC-1*α* and thus reducing oxidative stress and mitochondrial dysfunction could potentially limit muscle damage and degeneration.

3.2. PGC-1 and inflammation {#sec3.2}
---------------------------

Inflammation is a tissue process consisting of a series of molecular, cellular, and vascular phenomena with defensive purposes against physical, chemical, or biological aggression[@bib90]. As a process, it is focused on a specific area, though exceptions may occur in the case of systemic inflammation. In addition, inflammation is an immediate and unspecific response which can facilitate the development of a specific immune response. The inflammatory process is characterized by a migration of immune cells to the inflammatory focus. As a consequence of the inflammation, vasodilatation occurs along with an increase in the permeability of the blood vessels near the affected area, facilitating the arrival of leukocytes to the place of inflammation and the influx of other mediator molecules[@bib89]^,^[@bib91]. The ultimate goal of inflammation is to eliminate or inhibit the agent causing the infection or cell damage, and to allow the organism to recover to normal conditions, restoring the functionality of the affected tissue or organ[@bib92]. Inflammation is receiving increasing consideration due to its likely involvement in the development of various disorders, including MD[@bib93], [@bib94], [@bib95]. Since PGC-1 contributes to cellular respiration and mitochondrial biogenesis, its adequate function is essential for skeletal muscle. In this way, repression of PGC-1 and its associated inflammatory responses are present in many skeletal muscle diseases[@bib96]. In addition, PGC-1 also induces the expression and activation of several antioxidant enzymes, including catalase, Mn-superoxide dismutase (Mn-SOD), and GPX, contributing to the improvement of oxidative damage and inflammation[@bib59]^,^[@bib97].

Studies performed in different organs such as the heart, liver or kidneys evidenced that LPS injection significantly represses expression of *Pgc-1α* mRNA[@bib98], [@bib99], [@bib100]. In skeletal muscle, acute treatment with LPS or palmitate seems to exert a dual regulation, with increased PGC-1 expression in the short-term, followed by long-term repression[@bib101]^,^[@bib102]. Using myotubes (C2C12) and mouse primary myotubes as cell models, chronic treatment with tumor necrosis factor-*α* (TNF-*α*) has been found to significantly decrease expression of PGC-1 (both *α* and *β* isoforms)[@bib103]. In accordance with these data, chronic exposure to cigarette smoke resulted in TNF-*α*-mediated down-regulation of PGC-1*α* in C2C12 cells and in the soleus muscle of mice[@bib104]. In an interesting study, patients with advanced chronic obstructive pulmonary disease (COPD), with features of muscle wastage and elevated levels of TNF-*α*, showed lower expression of PGC-1*α* in vastus lateralis muscle biopsies with respect to healthy smoking control subjects[@bib105]. Taken together, this indicates that chronic inflammation leads to a repression of PGC-1 coactivators.

Conversely, diverse studies have reported that PGC-1 could prevent inflammation. In this manner, muscle-specific PGC-1*α* deficient mice presented increased interleukin (IL)-6 in both circulating blood and in skeletal muscle[@bib106]. A study investigated the effects of PGC-1*α* and *β* on inflammatory cytokines in C2C12 cells after stimulation with TNF-*α*, toll-like receptor agonists, and free fatty acids[@bib107]. PGC-1s activation suppressed the generation of several proinflammatory cytokines by targeting the NF-*κ*B signalling pathway and reducing the phosphorylation of P65. The same research group also found similar anti-inflammatory effects of PGC-1*α*/-1*β* in muscle-specific *Pgc-1α*/*1β* double transgenic mice. PGC-1s induced the expression of anti-inflammatory factors while suppressing pro-inflammatory IL-12, which is likely associated with a M2-type macrophage polarization in skeletal muscle[@bib108]. Similarly, PGC-1*β* has been reported as being capable of suppressing palmitic acid-induced inflammation by inhibiting macrophage NF-*κ*B P65[@bib109]. These results also suggest that elevated PGC-1s expression contributes to the instauration of an anti-inflammatory environment.

3.3. The role of PGC-1α in angiogenesis {#sec3.3}
---------------------------------------

Angiogenesis, an intricate and highly regulated process, is defined as the generation of newly formed blood vessels from preexisting vessels in order to supply oxygen and nutrients to various tissues. The purpose of angiogenesis is to meet metabolic demands under physiological (pregnancy, exercise, and embryonic development), and pathological conditions (such as tumor progression and metastasis)[@bib110], [@bib111], [@bib112]. Several growth factors, including vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), and angiopoietin are the main triggers of this process. Regulation of nutrient supply so as to provide an appropriate volume of metabolic demand is a highly essential factor for tissues such as skeletal muscle, due to their high metabolic rates. Due to the regulatory effects of PGC-1 on various metabolic functions in numerous tissues, recent studies have focused on the involvement of this coactivator in angiogenesis, as demonstrated in various *in vivo* and experimental studies. For example, Chinsomboon et al.[@bib113] reported that PGC-1*α* is involved in exercise-induced angiogenesis.

When compared with *Pgc-1α*^+/+^ mice, which had robust angiogenesis during voluntary exercise, *Pgc-1α*^--/--^ mice failed to increase their microvessel density. Exercise was shown to induce *β*-adrenergic signaling-dependent expression of PGC-1*α*. Overexpression of VEGF also contributes to PGC-1*α* induction, and this was found to be mediated by orphan nuclear receptor estrogen-related receptor alpha (ERR*α*). These findings illustrate that *β*-adrenergic activation of a PGC-1*α*/ERR*α*/VEGF pathway is involved in exercise-induced physiological angiogenesis in skeletal muscles[@bib114]. In another study by Geng et al.[@bib114], it was found that PGC-1*α* plays an important part in exercise-induced angiogenesis, and mitochondrial biogenesis in mouse skeletal muscles. In a study on mesenchymal stem cells (MSCs), Lu et al.[@bib115] found that PGC-1*α* upregulation resulted in the overexpression of hypoxia-inducible factors (HIF-1*α*), increased BCL-2/BAX ratio, downregulation of caspase 3, as well as consequent enhanced survival rates and increased expression of proangiogenic factors. In ischemic hindlimbs of diabetic rats, PGC-1*α* overexpression was found to significantly increase the perfusion of blood and microvessel density[@bib115]. Thom et al.[@bib116] showed truncated-PGC-1*α* induced VEGF expression and angiogenesis under hypoxic conditions. Conditioned media from cells expressing the truncated form of PGC-1*α* strongly prompts migration of endothelial cells and formation of capillary-like tubes. Transgenic expression of PGC-1*α*, specifically in skeletal muscle, induces angiogenesis *in vivo*[@bib116]. VEGF and HIF-1 were demonstrated to be direct targets of a PGC-1*α*-mediated increase in angiogenesis in various studies[@bib110], [@bib111], [@bib112]. Additionally, Rowe et al.[@bib6] demonstrated the effects of PGC-1*α* in muscle, significantly increasing angiogenesis in aged and in diabetic mice. PGC-1*α* induces the secretion of secreted phosphoprotein 1 (SPP1), and monocyte chemoattractant protein-1 (MCP-1) directed macrophage recruitment, which activates endothelial cells, smooth muscle cells, and pericytes. On the contrary, PGC-1*α* induction in *Spp1*^−/−^ mice leads to blunted arteriolarization as well as immature capillarization[@bib6]. The importance of PGC-1*α* in angiogenesis is significant to the point that deletion of this coactivator within skeletal muscle was reported to result in an impaired angiogenic program[@bib113]^,^[@bib114]^,^[@bib117], [@bib118], [@bib119], [@bib120].

4. Role of natural products as PGC-1***α*** modulators in DMD {#sec4}
=============================================================

Natural products have been found to exert protective activity against MD. Various natural products have been tested, such as green tea polyphenolics, quercetin, resveratrol, curcumin, and saponins, using cell and animal models of MD.

A primary culture of skeletal muscle cells was experimentally tested for the protective activity of green tea polyphenol mixture and EGCG against oxidative stress[@bib121]. Treatment of dystrophic cells with green tea polyphenol blend/EGCG improved the cell survival, whereas normal cells were protected by green tea polyphenol blend and not by EGCG.

Using an *mdx* mouse model, EGCG was tested for its protective activity against DMD. EGCG was injected subcutaneously (5 mg/kg) for 8 weeks[@bib122]. Improvements in blood chemistry (the reduced activity of serum kinase), muscle histological changes, and the electrophysiology of treated *mdx* mice were recorded. The numbers of fluorescent lipofuscin granules in soleus and diaphragm muscle were significantly reduced to 50% of control. With the EGCG treatment, the relative area of normal muscle fibers increased up to two-fold above control. The level of utrophin in the diaphragm muscles of treated mice was significantly increased by 17%. In a similar experiment, an *mdx* mouse dystrophy model was tested with green tea (0.01% or 0.05%, by weight) administered as a diet supplement[@bib123]. The treatment was found to significantly reduce necrosis in the fast-twitch muscle elongator digitorum longue, but with negligible impact on the slow-twitch soleus muscle. The treatment was also found to decrease oxidative stress in the *mdx* mouse model, thereby improving muscle health by retarding necrosis.

In a similar study, a dystrophic *mdx* mouse model was used to assess the pharmacological effects of green tea extract, including its major polyphenol compounds, EGCG, and pentoxifyllin[@bib124]. This revealed that the tested mice exhibited retarded necrosis of the extensor digitorum longus muscle. Phasic and tetanic tension was also increased, rising to normal values. Moreover, the ratio of phasic to tetanic tension was found to be corrected after the treatment. In a fatigue assay, the treated mice were found to exhibit 30%--50% more resistant phenotypes. There is no evidence in the literature indicating the mechanism for this protective activity of EGCG against DMD. However, a recent *in vitro* study has shown that an EGCG pre-treatment could exert a protective effect against oxidative damage induced by 1-methyl-4-phenyl-pyridine in a rat adrenal pheochromocytoma (PC12) cell line *via* the SIRT1/PGC-1*α* signaling pathway. The authors showed that mRNA expression of *Pgc-1α*, *Sod*, and *Gpx1* are upregulated following pre-treatment with EGCG. In addition, the protein levels of PGC-1*α* and SIRT1 were increased, suggesting that the SIRT1/PGC-1*α* pathway is one of the mechanisms by which EGCG exerts PC12 cellular protection against 1-methyl-4-phenyl-pyridine damage[@bib125].

As reported in section [3](#sec3){ref-type="sec"}, SIRT1, which is found in the nucleus, acts as a deacetylase on PGC-1*α*, leading to the formation of SIRT1-deacetylated PGC-1*α*.

Saponins, such as digitonin and tomatine, were found to increase the activity of antisense oligonucleotides against DMD[@bib126]. In the presence of saponins, a significant enhancement in antisense phosphorodiamidate morpholino oligomer which targeted delivery to dystrophin exon 23 was found in *mdx* mice. This improvement was up to 7 times that of phosphorodiamidate morpholino oligomer alone. Saponin was also found to have lower cytotoxicity. It was found that saponins increased the efficiency of antisense oligonucleotide delivery and treatment of MD. Furthermore, a particular kind of saponin, chikusetsu saponin V, was found to be able to attenuate oxidative stress induced by H~2~O~2~ in human neuroblastoma SH-SY5Y cells, by increasing the activation of SIRT1, PGC-1*α*, and Mn-SOD[@bib127]. Chikusetsu saponin V is found in *Panax japonicus* rhizome. The anti-oxidative and anti-inflammatory effects of *P. japonicus* saponins have been under investigation for the past two decades. He et al.[@bib128] showed that these compounds exert a cardioprotective effect in a rat model of acute myocardial ischemia.

Resveratrol was found to be effective against DMD. It increases the expression of nucleocytoplasmic shuttling protein SIRT1^126^ which positively impacts the activity of SOD, decreasing ROS levels, and increasing expression of PGC-1*α*[@bib85]^,^[@bib128]. PGC-1*α* was found to regulate type specification of muscle fiber (switching from fast to slow fiber types), oxidative capacity, and mitochondrial biogenesis[@bib129]. It also targets utrophin, a dystrophin homolog[@bib130], and acts as a therapeutic active molecule against DMD.

In an experiment using the *mdx* mouse model, 500 mg/kg/day resveratrol was administered to mice for 32 weeks, and the authors observed that resveratrol decreased muscle wasting compared to control. It also reduced oxidative damage and downregulated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, *α*-smooth muscle actin, and myofibroblast cells[@bib131].

In another experiment, *mdx* mice were treated with increasing dosages of resveratrol (0--400 mg/kg/day) for 8 weeks. It was found that at a 100 mg/kg/day dosage, the resveratrol increased fatigue resistance in slow-twitch soleus muscle and increased force in fast-twitch extensor digitorum longus muscle. However, resveratrol did not induce an increased resistance to injury in either muscle[@bib129]. A higher 400 mg/kg dosage resulted in a number of deaths, indicating the toxicity of this compound. But other experiments did not show death at similar or higher dosages[@bib130].

In another study, resveratrol (100 mg/kg) treatment for 8 weeks led to an improvement in rotarod performance, centrally nucleated fibers damage, and oxidative stress using 4--5 week-old male *mdx* mice[@bib131]. Using a similar experiment, *mdx* mice receiving reveratrol at a dosage of 100 mg/kg were found to possess higher activities of SIRT1 and PGC-1*α* after 6 weeks of treatment[@bib132]. When the time period was increased to 12 weeks, resveratrol was found to be effective in increasing mitochondrial biogenesis and upregulating the expression of slower myosin heavy chain isoforms. However, an increased dosage of 500 mg/kg was not found to be effective compared to the 100 mg/kg dosage.

Overall, the efficacy of resveratrol *in vivo* may be hampered by its low bioavailability, and caution should be considered when extrapolating its laboratory effects to *in vivo* studies. In fact, resveratrol exhibits lipophilic characteristics, which promote high absorption but also subsequent rapid elimination after the first hepatic passage, contributing to its low bioavailability. Despite this, resveratrol shows efficacy *in vivo*. This is likely due to a variety of mechanisms, such as the reconversion of metabolites (sulfates and glucuronides) to resveratrol upon arrival in target organs, the enterohepatic recirculation of resveratrol metabolites and their subsequent deconjugation and reabsorption in the small intestine, and the activity of its metabolites[@bib133], [@bib134], [@bib135].

Quercetin was found to activate SIRT1 and then PGC-1*α*, and stimulate mitochondrial biogenesis in skeletal muscles[@bib136]. It was found to exert antioxidant activity as well as mitochondrial biogenesis, and thus be beneficial against dystrophic skeletal muscle. In a study, supplementation with quercetin (0.2%) in three-month-old *mdx* mice for 6 months led to beneficial effects on the diaphragm[@bib136]. Under this treatment, inflammatory response and pro-fibrotic infiltration was attenuated along with an increased expression of oxidative genes and mitochondrial transcription factors.

Curcumin was also found to be effective against MD. In an experiment, *mdx* mice were given a diet containing curcumin (1%, *w*/*v*)[@bib137]. NF-*κ*B activity was unchanged in the muscle, but muscular contractile activity was improved against control. In another study, curcumin was administered (0.1--1 mg/kg, i.p.) for 10 days to *mdx* mice[@bib137]^,^[@bib138]. Curcumin was found to reduce muscle damage in *mdx* mice and reduce skeletal muscle necrosis and muscle fiber size. The dose of 1 mg/kg was found to produce improvements in muscle function. In vascular smooth muscle cells, curcumin was found to increase SOD synthesis and adenosine triphosphate (ATP) reduction, leading to the formation of AMPK, which increases NAD^+^ levels and induces SIRT1 activation[@bib139]. As a matter of fact, the beneficial effects of curcumin in MD could be due, at least in part, to its effect on SIRT1. Aside from these promising results obtained in animal models, the poor absorption, rapid metabolism, and systemic elimination of curcumin lead to lowered levels of the compound in plasma and tissue, blunting the possibility of implementing curcumin supplementation for human chronic disorders, such as DMD. Indeed, considering the progressive genetic nature of the disease, a short-term treatment is unlikely to positively impact long term muscular degeneration.

The identification of the molecular signaling contributing to the crosslink between natural products and PGC-1*α* remains a highly interesting subject. Trains of existing evidence suggest that PGC-1*α* transcription is highly regulated through the binding of transcription factors at its promoter, and these include myocyte enhancer factor 2 (MEF2), forkhead box class-O1 (FOXO1), activating transcription factor 2 (ATF2), and cyclic AMP response element-binding protein (CREB). These factors all enhance transcription of PGC-1*α*, and are each in turn modulated by different signaling pathways. In particular, AKT activation (*i*.*e*., by insulin) leads to cytoplasmic sequestration and inhibition of FOXO1, which physiologically binds and stimulates the promoter in skeletal muscle; p38 mitogen-activated protein kinase (p38 MAPK) activation (*i*.*e*., by exercise) phosporylates and activates MEF2 and ATF2, thus stimulates transcription; whereas calcineurin A (CnA) induces CREB and MEF2-mediated PGC-1*α* transcription. Importantly, posttranslational modifications of PGC-1*α* have also been shown to modulate its activity and levels by phosphorylation, acetylation, methylation, ubiquitination, and O-linked *N*-acetylglucosylation, in particular, by increasing transcription, p38 MAPK phosphorylation, and enhancement of PGC-1*α* activity[@bib140]. Conversely, glycogen synthase kinase 3b (GSK3b), also phosphorylates PGC-1*α*, enhancing its proteasomal degradation due to oxidative stress while in the nucleus, thus inhibiting its activity[@bib141].

Importantly, most natural products interact with molecules involved in key intracellular pathways, including direct or indirect interactions with AKT, GSK3b, and p38 MAPK. For example, several compounds present in natural products negatively target AKT, p38 MAPK, and GSK-3 signaling activities, leading to inhibition of inflammation responses (*i*.*e*., quercetin, curcumin, and berberin). This regulatory behavior has been proposed for potential treatment of a range of disorders, in particular those which involve inflammatory processes potentially contributing to abnormal proliferation and cancer growth[@bib142], whereas their role as intermediates in modulating PGC-1*α* transcription and phosphorylation is as yet to be elucidated.

5. Conclusions {#sec5}
==============

MD comprises a heterogeneous collection of disorders which are characterized by progressive weakness, loss of muscle strength, and degeneration. Since most forms of MD are genetic diseases, no effective treatment currently exists for these pathologies. In this sense, the search for new therapeutic targets which may contribute to a reduction in the development and progression of MD is necessary, as long as we are not able to effectively treat the origin of these diseases. One of these targets is PGC-1 and its cofactors, particularly PGC-1*α*, because it is inducible under physiological variations and is useful for increasing oxidative metabolism, mitochondrial biogenesis, angiogenesis, reducing oxidative stress, and inflammation ([Fig. 2](#fig2){ref-type="fig"}). Several natural compounds have shown a protective activity against MD in various cellular and animal models, increasing cell survival and reducing necrosis and levels of oxidative stress. We can highlight the induction of PGC-1*α* expression among the mechanisms of action of certain natural compounds, such as resveratrol and quercetin. However, the mechanisms of action involved in the observed improvements have not been studied in depth. In addition, there are currently no clinical trials with which to compare the results obtained in cell and animal models, therefore, the therapeutic use of these compounds, while promising, is still in a very embryonic state.Figure 2DMD pathogenesis and PGC-1*α* targets.Figure 2
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